Literature DB >> 6457936

Medroxyprogesterone acetate in human serum.

M Mathrubutham, K Fotherby.   

Abstract

Entities:  

Keywords:  Biology; Clinical Research; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Methods; Depo-provera; Family Planning; Hematological Effects; Hemic System; Injectables; Medroxyprogesterone Acetate; Physiology; Research Methodology

Mesh：

Substances：

Year:  1981        PMID： 6457936     DOI： 10.1016/0022-4731(81)90015-7

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN： 0022-4731            Impact factor:   4.292


× No keyword cloud information.
  10 in total

Review 1.  Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception.

Authors:  Frank Z Stanczyk
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

Review 2.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 3.  Clinical significance of differences in bioavailability of medroxyprogesterone acetate preparations.

Authors:  A D Stockdale; A Y Rostom
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

Review 4.  Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.

Authors:  Janet P Hapgood; Charu Kaushic; Zdenek Hel
Journal:  Endocr Rev       Date:  2018-02-01       Impact factor: 19.871

5.  Plasma concentrations of medroxyprogesterone acetate and megesterol acetate during long-term follow-up in patients treated for metastatic breast cancer.

Authors:  A A Miller; R Becher; C G Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

Review 6.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

7.  Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV?

Authors:  Chelsea B Polis; Sharon L Achilles; Zdenek Hel; Janet P Hapgood
Journal:  Contraception       Date:  2017-12-11       Impact factor: 3.375

8.  Effect of oral high-dose progestins on the disposition of antipyrine, digitoxin, and warfarin in patients with advanced breast cancer.

Authors:  S Lundgren; S Kvinnsland; E Utaaker; O Bakke; P M Ueland
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells.

Authors:  Radhika P Ghatge; Britta M Jacobsen; Stephanie A Schittone; Kathryn B Horwitz
Journal:  Breast Cancer Res       Date:  2005-11-02       Impact factor: 6.466

10.  An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancer.

Authors:  J R Johnson; T J Priestman; K Fotherby; K A Kelly; S G Priestman
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.